Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)

Condition(s) studied

Investigational drug(s) / intervention(s)

no intervention: no intervention

Study summary

Janus kinase (JAK) inhibitors are a new class of molecules available to the therapeutic arsenal for chronic inflammatory rheumatic diseases.The tolerance profile of this new class needs to be better defined and its use in real life further established.

The French Society of Rheumatologists intends to coordinate a prospective national registry study for this follow-up.

This registry will include at least 1500 Rheumatoid Arthritis (RA) and 150 patients with psoriatic arthritis from the start of treatment with JAK inhibitor and then followed for 5 years.

This registry is a longitudinal, multicentre, observational registry study. The objective of this national registry is to get a better understanding of the safety profiles of JAK inhibitors and get knowledge of their use in daily practice in order to optimize this use and potentially integrate JAK inhibitors into personalised medicine strategies.

This registry will generate efficacy data, especially therapeutic maintenance, observation, allowing inter-registry comparisons with other biologic compounds in the French population, and can be aggregated with other similar registries in other countries.

Eligibility

Primary outcome measure(s)

• Therapeutic maintenance of JAK inhibitors — From the beginning of the study up to Year 1
  The therapeutic maintenance will be measured by the retention rate ie the percentage of patients remaining treated by JAK inhibitors.

Trial sites (60)

+ 20 more sites — see the full list on the official registry below.

More Societe Francaise de Rhumatologie trials in France

Other trials for the same condition